<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374267</url>
  </required_header>
  <id_info>
    <org_study_id>iOM-110363</org_study_id>
    <nct_id>NCT03374267</nct_id>
  </id_info>
  <brief_title>Registry Platform Urologic Cancer</brief_title>
  <acronym>CARAT</acronym>
  <official_title>Clinical Research Platform On Urologic Cancer Treatment And Outcome (Registry Platform Urologic Cancer; CARAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to set up a national, prospective, longitudinal, multicenter&#xD;
      cohort study with associated satellites, a tumor registry platform, to document uniform data&#xD;
      on characteristics, molecular diagnostics, treatment and course of disease, to collect&#xD;
      patient-reported outcomes and to establish a decentralized biobank for patients with advanced&#xD;
      renal cell carcinoma or advanced urothelial cancer in Germany.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CARAT is a national, observational, prospective, longitudinal, multicenter cohort study&#xD;
      (tumor registry platform) with the purpose to record information on the antineoplastic&#xD;
      treatment of renal cell carcinoma and urothelial cancer in Germany. The registry will follow&#xD;
      patients with advanced renal carcinoma for up to three years, and patients with advanced&#xD;
      urothelial cancer for up to two years. It will identify common therapeutic sequences and&#xD;
      changes in the treatment of the disease. At inclusion, data in patient characteristics,&#xD;
      comorbidities, tumor characteristics and previous treatments are collected. During the course&#xD;
      of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are&#xD;
      documented.&#xD;
&#xD;
      Health-related quality of life (HRQoL) in patients with renal cell carcinoma or urothelial&#xD;
      cancel will be evaluated for up to two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Course of treatment (treatment reality)</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of anamnestic data and therapy sequences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of response rates per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of progression-free survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of overall survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome)</measure>
    <time_frame>2 years per patient</time_frame>
    <description>Cohort aRCC: National Comprehensive Cancer Network/ Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) Cohort aUBC: NCCN/FACT Bladder Symptom Index (NCCN-FACT FBlSI-18, Version 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment symptom related quality of life</measure>
    <time_frame>2 years per patient</time_frame>
    <description>Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) - Items/Scores cohort aRCC: 3/7/15/22/24/27/28/50/51; Items/Scores cohort aUBC: 3/7/15/22/24/27/28/39/45/50/51</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>aRCC</arm_group_label>
    <description>Patients with advanced renall cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aUBC</arm_group_label>
    <description>Patients with advanced urothelial carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine care as per site standard.</intervention_name>
    <description>Physician's choice according to patient's needs.</description>
    <arm_group_label>aRCC</arm_group_label>
    <arm_group_label>aUBC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with advanced renal cell carcionoma (aRCC) or advanced urothelial cancer&#xD;
        (aUBC) requiring systemic treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male patients with aRCC or aUBC (locally advanced, inoperable or&#xD;
             metastatic)&#xD;
&#xD;
          -  Patients at start of their first-line systemic treatment for aRCC or aUBC&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
               -  Patients participating in the PRO module: signing of in-formed consent form and&#xD;
                  completion of baseline questionnaire before start of initial systemic treatment&#xD;
&#xD;
               -  Patients not participating in the PRO module: within twelve weeks after start of&#xD;
                  systemic first-line for aRCC or aUBC&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior systemic therapy for aRCC or aUBC&#xD;
&#xD;
          -  No systemic treatment for aRCC or aUBC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Staehler, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Urologische Klinik und Poliklinik, Klinikum der Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Goebell, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Urologische Universitätsklinik, Waldkrankenhaus St. Marien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lothar Müller, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Onkologie Leer - Emden - Papenburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Viktor Grünwald, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Essen (AöR), Westdeutsches Tumorzentrum Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carsten Grüllich, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Caritas Krankenhaus, Lebach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Marschner, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Praxis für interdisziplinäre Onkologie &amp; Hämatologie, Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela Koska</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple sites, Germany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO AG</last_name>
      <phone>+49 761 152420</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

